Ajanta Pharma reported a strong Q2 FY 2027 performance with revenue growing 33% to Rs 1,794 crore. Profits rose 49% year-on-year to Rs 388 crore, fueled by double-digit growth across its India, US, and Africa markets. Improved operational efficiency pushed EBITDA margins to 30%.
Ajanta Pharma Q2 FY 2027 Profit Surges 49% to Rs 388 Crore
Revenue grew by 33% to Rs 1,794 crore, while Profit After Tax (PAT) climbed 49% to Rs 388 crore.
Reader Takeaway: Strong global growth across key markets and margin expansion signal robust operational health for Ajanta Pharma.
What just happened
Ajanta Pharma Limited released its unaudited financial results for the quarter ended September 30, 2026. The company reported a significant performance boost compared to the same period last year. Revenue rose to Rs 1,794 crore, while adjusted EBITDA reached Rs 543 crore, reflecting improved operating margins of 30% compared to 27% a year ago.
Why this matters
The company’s performance was driven by balanced growth across geographies. India Branded Generics grew 16% to Rs 504 crore, while the US Generic business posted a 41% jump to Rs 484 crore. Notably, the Africa Institution segment witnessed a sharp 259% rise to Rs 116 crore. These gains suggest that Ajanta’s diversified portfolio is effectively mitigating localized market risks.
What changes now
Investors now have confirmation of the firm's growth trajectory in the first half of FY 2027. With Return on Capital Employed (ROCE) at 41% and Return on Net Worth (RONW) at 31%, the company is demonstrating high capital efficiency. The focus shifts toward the conversion of its 17 pending US FDA ANDA approvals into commercialized products.
Risks to watch
While performance remains strong, investors should monitor competitive pressures in international markets and potential supply chain or regulatory hurdles that could impact the US portfolio. Sustaining margin expansion amid potential inflationary pressures in raw material costs remains a key monitorable.
What to track next
The primary focus remains on the progress of pending US FDA ANDA applications and the company’s ability to sustain its premium over the Indian Pharmaceutical Market (IPM) growth, which currently stands at 27% per IQVIA data.